Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Receptor tyrosine kinases (RTKs) orchestrate embryonic development and tissue homeostasis by controlling key cellular processes like growth and proliferation. Consequently, the vast majority of the 58 RTKs in humans are linked to cancer or metabolic disorders. For instance, RTKs represent known oncogenic drivers (such as EGFR in non‐small cell lung cancer), contribute to cancer hallmarks (such as VEGFR in pro‐tumor angiogenesis), and mediate resistance to therapeutics or hormones (such as the Insulin Receptor in diabetes). Classically, RTKs transduce signals through various modes of ligand‐induced receptor dimerization and subsequent tyrosine kinase‐mediated signaling; however, ~10% of all metazoan RTKs are pseudokinases—that is, they lack the capability to catalyze phosphotransfer. Our objective is to ascertain how RTK pseudokinases relay extracellular cues without kinase activity and whether they can be targeted therapeutically. Using structural, biophysical, and cell signaling approaches, we investigated this class of RTKs to shed light on potential non‐catalytic signaling mechanisms. We identified structural elements conserved between the pseudokinases and their kinase relatives, found their pseudokinase domains to be conformationally dynamic, and uncovered a putative route to drugging these receptors via “conformational disrupting” small molecules. Our findings suggest that RTK pseudokinases could serve as viable drug targets and set the scene for future dissection of signaling pathways that have long been considered enigmatic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Defining a new nomenclature for the structures of active and inactive kinases
Modi, V., & Dunbrack, R. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814279116 · Cited by 367
Oncogenic ERBB3 mutations in human cancers.
Jaiswal, B. S., Kljavin, N. M., Stawiski, E. W., Chan, E., Parikh, C., Durinck, S., Chaudhuri, S., Pujara, K., Guillory, J., Edgar, K. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.012 · Cited by 350
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Jura, N., Shan, Y., Cao, X., Shaw, D. E., & Kuriyan, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912101106 · Cited by 338 · cited 6×
“By contrast, the ErbB3 activation loop adopts a different conformation – instead resembling the inactive EGFR kinase domain (Jura et al., 2009; Shi et al., 2010).”
BackgroundMethodInfluentialCatalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310 · cited 1×
“Many effectors and activators bind to the N-lobe region of other kinases that is the focus of the conformational changes described here (Jura et al., 2011).”
BackgroundYamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
Ba/F3 cells and their use in kinase drug discovery
Warmuth, M., Kim, S., Gu, X.-J., Xia, G., & Adrián, F. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328011a25f · Cited by 240 · cited 12×
“Even if modulation of the properties of the pseudokinase domain by small molecules proves insufficient to block pseudokinase function, the ligands developed for the ATP-binding site of these proteins could instead be used for developing proteolysis targeting chimeras (PROTACs), as reported for both kinase-active RTKs…”
MethodInfluentialLittlefield, P., Liu, L., Mysore, V., Shan, Y., Shaw, D. E., & Jura, N. (2014) · Science Signaling · doi:10.1126/scisignal.2005786 · Cited by 126
Cited by
Allosteric activation of the co-receptor BAK1 by the EFR receptor kinase initiates immune signaling
Mühlenbeck, H., Tsutsui, Y., Lemmon, M. A., Bender, K. W., & Zipfel, C. (2023) · doi:10.1101/2023.08.23.554490 · Cited by 3
Self-citation
Metadata
- Authors
- Sheetz, J. B., Mathea, S., Karvonen, H., Malhotra, K., Chatterjee, D., Niininen, W., Perttilä, R., Preuss, F., Suresh, K., Stayrook, S. E., Tsutsui, Y., Radhakrishnan, R., Ungureanu, D., Knapp, S., & Lemmon, M. A.
- Venue
- Molecular Cell
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 79
- Issue
- 3
- Pages
- 390-405.e7
- ISSN
- 1097-2765 (ISSN-L)
- OpenAlex
- W3039913026
- Cited by
- 105
- References
- 9
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. https://app.cochat.ai/papers/10.1016/j.molcel.2020.06.018
- The paper
- Sheetz, J. B., Mathea, S., Karvonen, H., Malhotra, K., Chatterjee, D., Niininen, W., Perttilä, R., Preuss, F., Suresh, K., Stayrook, S. E., Tsutsui, Y., Radhakrishnan, R., Ungureanu, D., Knapp, S., & Lemmon, M. A. (2020). Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. Molecular Cell. https://doi.org/10.1016/j.molcel.2020.06.018
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.